Merck presents first Phase 3 INTerpath-001 data on intismeran plus Keytruda in resected melanoma at ESMO 2026
MRK•Merck said it will present the first Phase 3 INTerpath-001 data on intismeran plus Keytruda in resected melanoma at ESMO 2026. The results have not yet been presented; three late-breaking Presidential Symposia will also feature endometrial cancer studies.
1. Planned ESMO presentations
Merck flagged Phase 3 data from its oncology pipeline for presentation at ESMO 2026 in Madrid. Readouts include intismeran autogene with Keytruda in resected melanoma, sacituzumab tirumotecan in post-treatment endometrial cancer, and Keytruda monotherapy as an initial treatment option in dMMR advanced or recurrent endometrial cancer.
